Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01750918
Title BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

Therapies

Fluorouracil

Dabrafenib + Panitumumab

Dabrafenib + Panitumumab + Trametinib

Panitumumab + Trametinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST